Clinical trials
Solid Tumor Cancer clinical trials
Below are recruiting solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,461 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05539833RecruitingEarly Phase 1
TCR-T cell therapy for HLA-A2 positive solid tumors
This early-phase study tests a personalized immune-cell treatment (TCR-T cells) made from your own immune cells. You may qualify if you have a solid tumor that shows a specific target on tumor cells and your body type (HLA-A2) matches what the therapy needs.
Nanning, GuangxiAges 18–70 - NCT05471856RecruitingPhase 1
Test different doses of cancer drugs with ezabenlimab
This Phase 1 trial tests how different doses of a study drug (BI 1703880) work and how safe they are when given with ezabenlimab for advanced solid tumors. It’s for people whose cancer can’t be removed with surgery and who have tried standard treatments or can’t get them.
Los Angeles, CaliforniaAges 18 years+ - NCT05580796RecruitingEarly Phase 1
TCR-T cell therapy for HLA-A*02 positive solid tumors
This trial tests a personalized immune-cell treatment made from your own blood to target certain solid tumors. You may be eligible if your tumor has a specific protein pattern and you have tried standard treatments without success.
Beijing, Beijing MunicipalityAges 18–70 - NCT04891198RecruitingPhase 2
Envafolimumab for advanced cancers after other treatments
This trial tests envafolimumab, an immune therapy given alone, in people with advanced solid tumors that can’t be removed by surgery or have spread. It’s for patients whose cancer has grown despite (or they couldn’t tolerate) standard treatment, and it aims to find whether this drug can shrink tumors or slow growth.
BeijingAges 18 years+ - NCT05244551RecruitingPhase 1
First study drug for advanced cancers with FGFR changes
This early-phase study tests the safety and best dose of ABSK061 in people with advanced solid tumors. It may help people whose cancers have specific FGFR2/3 gene changes, especially urothelial cancer or cholangiocarcinoma.
Dallas, TexasAges 18 years+ - NCT05217693RecruitingPhase 1
First study drug BB-1705 for advanced solid tumors
This Phase 1 trial tests BB-1705 in people with advanced or metastatic (spread) solid tumors that cannot be removed with surgery. It mainly focuses on safety and how the drug behaves in the body, and may offer an option for patients when standard treatments have not worked.
BeijingAges 18–78 - NCT05436093Recruiting
PET scan using a tumor-targeting probe in solid tumors
This trial studies whether a special PET scan probe that targets CLDN18.2 can help show solid tumors in the body. If you have a solid tumor that can be measured on scan, you may be invited to have imaging with the probe.
Beijing, Beijing MunicipalityAges 18–75 - NCT04928612RecruitingPhase 1
CBP-1018 for advanced cancers that no standard treatment helped
This early-phase study tests CBP-1018 in people with advanced solid tumors, such as prostate, kidney, or certain lung cancers. It aims to see how the drug works and whether it’s safe enough to continue studying.
Guangzhou, GuangdongAges 18 years+ - NCT06730659RecruitingPhase 1
CHT101 for CD70-positive advanced solid tumors
This study tests a new drug called CHT101 for people with advanced solid tumors that have a specific protein (CD70) on the cancer cells. It may be an option if standard treatments have already been tried and failed.
TianjinAges 18–70 - NCT05036226RecruitingPhase 1/Phase 2
COAST therapy for advanced prostate or other solid tumors
This early-phase trial tests the COAST therapy approach in people with advanced solid tumor cancers or advanced prostate cancer that has continued to grow despite standard treatments. The study aims to see how well the treatment works and whether it is safe enough to continue studying.
Charleston, South CarolinaAges 18 years+ - NCT04942717Recruiting
Talking about health values with Spanish or English-speaking patients
This study tests an approach for discussing and sharing what patients value about their health, and adapting it for Latinx communities. It involves separate interviews with patients, families/caregivers, and oncology clinicians to improve how the intervention works and is understood.
New York, New YorkAges 21 years+ - NCT04685226RecruitingPhase 1/Phase 2
Testing ICP-723 for advanced solid tumors you can’t remove
This trial studies ICP-723 (a new medicine) in people with advanced cancers that cannot be removed with surgery, and in some primary brain (CNS) tumors. It’s an early-phase study (Phase 1/2) to see how the treatment works and how safe it is.
Hefei, AnhuiAges 12 years+ - NCT03810339RecruitingPhase 2
Check a POLE/POLD cancer drug for non–MSI-high tumors
This Phase 2 trial studies toripalimab (JS001), given alone, in people whose tumors have specific POLE or POLD gene mutations but do not have MSI-H/dMMR. If it works, it may help shrink or control advanced solid tumors that have not responded to standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT04282031RecruitingPhase 1/Phase 2
BPI-1178 for advanced breast cancer or solid tumors
This early-phase study tests BPI-1178 in people with advanced (stage 4 or hard-to-treat) solid tumors, including HR+/HER2- breast cancer. It looks at how well the treatment works and how safe it is, especially after standard treatments have stopped working or aren’t an option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04219254RecruitingPhase 1/Phase 2
Testing BI-1206 with pembrolizumab for advanced solid cancers
This early-phase trial studies BI-1206 together with pembrolizumab to treat advanced solid tumors. It may be an option if your cancer has progressed after prior anti–PD-1/PD-L1 treatment (or, in some groups, if standard treatments aren’t suitable).
Los Angeles, CaliforniaAges 18 years+ - NCT06973863RecruitingPhase 1
Study of PEP08 for advanced solid tumors with MTAP deletion
This trial tests a new drug called PEP08 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). It might be an option if standard treatments no longer work or cause too many side effects.
Wentworthville, New South WalesAges 18 years+ - NCT06962254RecruitingPhase 1
Imatinib and Trametinib for KRAS-mutated solid tumors
This trial tests a combination of two targeted drugs, imatinib and trametinib, for people with advanced solid tumors that have a specific KRAS mutation (G12X). It may be an option if standard treatments have stopped working or are not available.
Taichung, TaichungAges 20 years+ - NCT06497010RecruitingEarly Phase 1
Personalized mRNA cancer vaccine for advanced solid tumors
This trial tests a personalized mRNA vaccine (InnoPCV) designed from your own tumor's genetic profile to train your immune system to fight advanced solid tumors. It is for people who have not had tumor vaccines or CAR-T therapy before and can provide a tumor sample for customized vaccine creation.
Guiyang, China/GuizhouAges 18–75 - NCT07671534RecruitingPhase 2
Metronomic chemotherapy with gemcitabine, mitomycin C, and thalidomide for advanced solid tumors
This trial tests a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in a low, frequent 'metronomic' schedule to treat advanced solid tumors that have already been treated. The goal is to see if this approach can slow or stop tumor growth with fewer side effects.
Santa Monica, CaliforniaAges 18 years+ - NCT06208410RecruitingPhase 1/Phase 2
JS105 plus other treatments for advanced solid tumors
This trial tests a new drug called JS105 combined with other anti-cancer therapies for people with certain advanced breast, ovarian, endometrial, or cervical cancers. It aims to find out if these combinations are safe and effective.
Zhengzhou, HenanAges 18–75 - NCT03739827Recruiting
Study rare solid tumors and collect your health samples
This study follows people (and sometimes family members) connected to rare solid tumors and collects health information and samples (biospecimens). It helps researchers understand how these cancers develop and builds resources for future research, which may benefit you by contributing to better tailored care for rare cancers.
Bethesda, MarylandAges 4 weeks+ - NCT07656116RecruitingPhase 1
Oncolytic virus therapy for advanced solid tumors
This trial tests a virus-based treatment for people with advanced solid tumors that haven't responded to standard treatments. The virus is designed to infect and kill cancer cells while leaving healthy cells alone.
Langfang, HebeiAges 18 years+ - NCT04469530RecruitingPhase 2
Sirolimus plus low-dose chemotherapy for high-risk childhood tumors
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
Atlanta, GeorgiaAges 1–30 - NCT07139067RecruitingPhase 1
YK1101 for advanced solid tumors
This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.
BeijingAges 18–75
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor cancer?
- Yes. Clin2 currently lists 1,461 recruiting solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.